MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bjh.17447

Медицинская библиотека · British journal of haematology · 2021

Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.

Kim Dennis D H, Novitzky-Basso Igor, Kim Taehyung S, Atenafu Eshetu G, Forrest Donna, Savoie Lynn, Bence-Bruckler Isabelle, Keating Mary-Margaret, Busque Lambert, Delage Robert, Xenocostas Anargyros, Liew Elena, Paulson Kristjan, Stockley Tracy, Laneuville Pierre, Lipton Jeffrey H, Kamel-Reid Suzanne, Leber Brian

Клиническое исследование I фазыСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Although total duration of tyrosine kinase inhibitor (TKI) therapy and of molecular response at 4 log reduction or deeper (MR4) correlates with treatment-free remission (TFR) success after TKI discontinuation, the optimal cut-off values of the duration remain unresolved. Thus, 131 patients were enrolled into the Canadian TKI discontinuation study. The molecular relapse-free survival (mRFS) was defined from imatinib discontinuation till molecular recurrence, that is, major molecular response (MMR) loss and/or MR4 loss. We evaluated mRFS at 12 months after imatinib discontinuation, analyzed it according to the imatinib treatment duration and MR4 duration, and calculated P value, positive (PPV) and negative predictive value (NPV) in the yearly cut-off period of time. The shortest cut-off was sought that met the joint criteria of a P value ≤ 0·05, PPV ≥ 60% and NPV ≥ 60%. We propose six years as the shortest imatinib duration cut-off with a P value 0·01, PPV 68% and NPV 62%: The patients treated with imatinib duration ≥ 6 years showed a superior mRFS rate (61·8%) compared to those with less treatment (36·0%). Also, 4·5 years MR4 duration as the shortest cut-off with a P value 0·003, PPV 63% and NPV 61%: those with MR4 duration ≥ 4·5 years showed a higher mRFS rate (64·2%) than those with a shorter MR4 duration (41·9%).

Для цитирования: Kim Dennis D H, Novitzky-Basso Igor, Kim Taehyung S, Atenafu Eshetu G, Forrest Donna, Savoie Lynn, Bence-Bruckler Isabelle, Keating Mary-Margaret, Busque Lambert, Delage Robert, Xenocostas Anargyros, Liew Elena, Paulson Kristjan, Stockley Tracy, Laneuville Pierre, Lipton Jeffrey H, Kamel-Reid Suzanne, Leber Brian. Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.. British journal of haematology. 2021. DOI: 10.1111/bjh.17447.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.